Clinical trials: Acute Myeloid Leukemia Without Maturation
Leukemia
Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531
RATIONALE: DNA analysis of blood and tissue samples may help doctors predict how well patients will respond to treatment. It may also help doctors learn more about how gemtuzumab ozogamicin works in the body.
- Trial name
- NCT01407757
- Testing
- DNA analysis, gene expression analysis, laboratory biomarker analysis
- Volunteers
- 1,000 people
- Sponsor
- Children's Oncology Group
Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7)
Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
This research study is studying identification of de novo Fanconi anemia in younger patients with newly diagnosed acute myeloid leukemia.
- Conditions
- Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT01146210
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
Leukemia, Lymphoma
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005092
- Testing
- Cyclophosphamide, Psoralen, Thiotepa
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
This phase I trial is studying the side effects and best dose of flavopiridol in treating patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, or chronic myelogenous leukemia.
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00101231
- Testing
- alvocidib
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
RATIONALE: Giving high doses of chemotherapy drugs, such as busulfan and cyclophosphamide, before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT01177371
- Testing
- busulfan, cyclophosphamide, allogeneic bone marrow transplantation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Leukemia
Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003758
- Testing
- cytarabine, idarubicin, allogeneic bone marrow transplantation
- Where
- 16 sites in Belgium, Croatia and 5 more
- Volunteers
- 60 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
This phase II trial is studying the side effects and best dose of bortezomib and to see how well it works when given together with combination chemotherapy in treating younger patients with recurrent, refractory, or secondary…
- Conditions
- Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1)
- Trial name
- NCT00666588
- Testing
- idarubicin, cytarabine, bortezomib
- Where
- 82 sites in United States, Australia and 1 more
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow transplantation may allow the doctor to give…
- Trial name
- NCT00002549
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- 75 sites in Austria, Belgium and 9 more
- Volunteers
- 1,520 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Leukemia
Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating children who have undergone bone marrow transplantation…
- Trial name
- NCT00009698
- Testing
- aldesleukin
- Where
- 119 sites in United States, Australia and 4 more
- Volunteers
- 1 people
- Sponsor
- Children's Oncology Group
Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7)
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome.
- Conditions
- Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b)
- Trial name
- NCT00002798
- Testing
- asparaginase, daunorubicin hydrochloride, fludarabine phosphate
- Where
- United States
- Volunteers
- 880 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and lean more about biomarkers related to cancer.
- Trial name
- NCT01385150
- Testing
- mutation analysis, protein analysis, laboratory biomarker analysis
- Volunteers
- 220 people
- Sponsor
- Eastern Cooperative Oncology Group
Leukemia
Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia
RATIONALE: A screening test, such as My Profile Pediatric Assay, may help doctors predict a patient's risk of relapse and plan better treatment for acute myeloid leukemia.
- Trial name
- NCT01438138
- Testing
- diagnostic laboratory biomarker analysis
- Volunteers
- 98 people
- Sponsor
- Children's Oncology Group
Leukemia, Myelodysplastic Syndromes
Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00005593
- Testing
- carboplatin, fludarabine phosphate, topotecan hydrochloride
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Case Comprehensive Cancer Center
Leukemia, Lymphoma
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00003396
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, cyclophosphamide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Maryland, Baltimore
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML
The purpose of this clinical trial is to study genetically engineered NK92 cell therapy in treating patients with CD33 positive acute myeloid leukemias that is relapsed (after stem cell transplantation or intensive chemotherapy)…
- Conditions
- Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With Maturation, Acute Myeloid Leukemia Without Maturation
- Trial name
- NCT02944162
- Testing
- anti-CD33 CAR-NK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Leukemia, Neutropenia
Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00002658
- Testing
- filgrastim, amsacrine, cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Medical Research Council
Leukemia
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00372619
- Testing
- clofarabine, cytarabine, methotrexate
- Where
- 79 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- Children's Oncology Group
Leukemia
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00070174
- Testing
- asparaginase, busulfan, cyclophosphamide
- Where
- 148 sites in United States, Australia and 3 more
- Volunteers
- 350 people
- Sponsor
- Children's Oncology Group
Leukemia
Biomarkers in Predicting Response to Treatment in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of bone marrow from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.
- Trial name
- NCT01321385
- Testing
- laboratory biomarker analysis, study of socioeconomic and demographic variables
- Volunteers
- 97 people
- Sponsor
- Children's Oncology Group